Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A second phase Ib/II study combining IMCgp100 with merestinib in metastatic uveal melanoma

Next Previous
Trial Profile

A second phase Ib/II study combining IMCgp100 with merestinib in metastatic uveal melanoma

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Merestinib (Primary) ; Tebentafusp (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 11 Aug 2021 According to a Immunocore media release, submission of a Market Authorization Application (MAA) to the European Medicines Agency (EMA) accelerated to Q3. EMA granted tebentafusp accelerated assessment procedure for this MAA.
    • 25 Jan 2016 According to a Immunocore media release, IMCgp100 has been granted Orphan drug designation by U.S. FDA for the treatment of uveal melanoma.
    • 09 Sep 2015 According to a Immunocore media release, IMCgp100 has been accepted to participate in the European Medicines Agency's (EMA) Adaptive Pathways (formerly Adaptive Licensing) pilot programme and plans to seek conditional approval for IMCgp100 for the treatment of patients with metastatic uveal melanoma, which will be subject to the successful completion of this study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top